Effect of Vitamin D on Cognitive Decline of Patients With Memory Complaint
NCT02185222, Phase 3, Completed, University Hospital, Tours
Trial 11
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effect of Vitamin D on Cognitive Decline of Patients With Memory Complaint | ClinicalTrials.gov |
| NCT number | NCT02185222 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Phase 3 | ClinicalTrials.gov |
| Enrollment | 68 participants, actual | ClinicalTrials.gov |
| Lead sponsor | University Hospital, Tours | ClinicalTrials.gov |
| Conditions | Memory Disorders, Age-Related Cognitive Decline | ClinicalTrials.gov |
| Interventions | Cholecalciferol 100 000 UI, Placebo | ClinicalTrials.gov |
| First posted | 2014-07-09 | ClinicalTrials.gov |
| Last updated | 2020-11-04 | ClinicalTrials.gov |
| Other registries' IDs | eudract:2013-005110-36 | ClinicalTrials.gov |
Registered outcomes 20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Changes from baseline memory functions measured by the score of the total recall test from Free and Cued Selective Recall Reminding Test (Rappel Libre / Rappel Indicé 16 items : RL/RI 16) at one year and at two years | Baseline (at inclusion), one year and two years | The score of the total recall test from Free and Cued Selective Recall Reminding Test (RL/RI 16) is recommended by a European Task Force consensus. | ClinicalTrials.gov |
| Secondary | Changes from baseline global efficiency measured by the Mc Nair scale at one year and at two years | Baseline (inclusion), one year and two years | ClinicalTrials.gov | |
| Secondary | Evolution of anaemia evaluated by red blood cells count | Baseline (pre-inclusion), one year and two years | ClinicalTrials.gov | |
| Secondary | Evolution of plasma calcium and albumin concentration | Baseline (pre-inclusion), 45 days, one year and two years | ClinicalTrials.gov | |
| Secondary | Evolution of urinary calcium and creatinine concentration | 45 days, one year and two years | ClinicalTrials.gov | |
| Secondary | All adverse events | Up to two years | ClinicalTrials.gov | |
| Secondary | Serum level of 25-hydroxy vitamine D (25-OH D) measured to study observance | Baseline (pre-inclusion), one year and two years | ClinicalTrials.gov | |
| Secondary | Changes from baseline global efficiency measured by the Mini Mental State Examination at one year and at two years | Baseline (at inclusion), one year and two years | ClinicalTrials.gov | |
| Secondary | Changes from baseline global efficiency measured by the Montreal Cognitive Assessment at one year and at two years | Baseline (at inclusion), one year and two years | ClinicalTrials.gov | |
| Secondary | Changes from baseline instrumental activity of daily living measured by 8 items at one year and at two years | Baseline (at inclusion), one year and two years | ClinicalTrials.gov | |
| Secondary | Changes from baseline language measured by the "test de denomination orale d'images" (DO-80) at one year and at two years | Baseline (at inclusion), one year and two years | ClinicalTrials.gov | |
| Secondary | Memory function measured by a visual test : delayed matching to sample 48 items (DMS-48) | Baseline at inclusion | ClinicalTrials.gov | |
| Secondary | Changes from baseline executive functions measured by the stroop test at one year and at two years | Baseline (at inclusion), one year and two years | ClinicalTrials.gov | |
| Secondary | Changes from baseline executive functions measured by the verbal fluency at one year and at two years | Baseline (at inclusion), one year and two years | ClinicalTrials.gov | |
| Secondary | Changes from baseline executive functions measured by the Trail Making Test part B at one year and at two years | Baseline (at inclusion), one year and two years | ClinicalTrials.gov | |
| Secondary | Changes from baseline attention and speed processing measured by the Trail Making Test part A at one year and at two years | Baseline (at inclusion), one year and two years | ClinicalTrials.gov | |
| Secondary | Changes from baseline attention and speed processing measured by the Digit symbol test at one year and at two years | Baseline (at inclusion), one year and two years | ClinicalTrials.gov | |
| Secondary | Changes from baseline visuospatial study measured by the Rey figure (copy) at one year and at two years | Baseline (at inclusion), one year and two years | ClinicalTrials.gov | |
| Secondary | Changes from baseline praxis at one year and at two years | Baseline (at inclusion), one year and two years | Production of symbolic gesture, imitation utilization gesture, non sense gesture imitation | ClinicalTrials.gov |
| Secondary | Changes from baseline depressive symptoms measured by the Montgomery and Asberg Depression Rating Scale at one year and at two years | Baseline (at inclusion), one year and two years | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 6
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Delayed Match-to-Sample | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Symbol Coding | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)